Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report.
10.1007/s11684-018-0635-y
- Author:
Bingshan LIU
1
;
Roshni NARURKAR
2
;
Madhura HANMANTGAD
2
;
Wahib ZAFAR
2
;
Yongping SONG
1
;
Delong LIU
3
Author Information
1. The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450003, China.
2. Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, 10595, USA.
3. The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, 450003, China. delong_liu@nymc.edu.
- Publication Type:Case Reports
- Keywords:
AML;
cytarabine;
leukemia;
venetoclax
- MeSH:
Aged;
Bridged Bicyclo Compounds, Heterocyclic;
administration & dosage;
Combined Modality Therapy;
Cytarabine;
administration & dosage;
Fatal Outcome;
Hematopoietic Stem Cell Transplantation;
Humans;
Leukemia, Myeloid, Acute;
drug therapy;
genetics;
Male;
Recurrence;
Remission Induction;
Sulfonamides;
administration & dosage
- From:
Frontiers of Medicine
2018;12(5):593-599
- CountryChina
- Language:English
-
Abstract:
Conventional combination therapies have not resulted in considerable progress in the treatment of acute myeloid leukemia (AML). Elderly patients with AML and poor risk factors have grave prognosis. Midostaurin has been recently approved for the treatment of FLT-3-mutated AML. Venetoclax, a BCL-2 inhibitor, has been approved for the treatment of relapsed and/or refractory chronic lymphoid leukemia. Clinical trials on applying venetoclax in combination with cytarabine and other agents to treat various hematological malignancies are currently underway. Here, we present a case of a male patient with poor performance status and who developed AML following allogeneic hematopoietic stem cell transplant for high-risk myelodysplasia. The patient with high risk AML achieved complete response to the combined treatment regimen of low-dose cytarabine and venetoclax. Furthermore, we reviewed current clinical trials on the use of venetoclax for hematological malignancies.
